Huntington's disease: From molecular basis to therapeutic advances

International Journal of Biochemistry and Cell Biology

Volumn 43, Issue 1, 2011, Pages 20-24

  Krobitsch, Sylvia ^a   Kazantsev, Aleksey G ^a,b  

^a MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Huntingtin; Huntington's disease; Neurodegeneration; Neuroprotection

Indexed keywords

HUNTINGTIN; POLYGLUTAMINE; TETRABENAZINE;

ARTICLE; CELL FUNCTION; DISEASE COURSE; HUMAN; HUNTINGTON CHOREA; NEUROPATHOLOGY; NEUROPROTECTION; PATHOGENESIS; PATHOPHYSIOLOGY;

EID: 78650228452     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2010.10.014     Document Type: Short Survey

References (30)

1. HDCRG A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell 72 1993 971 983
2. A. Aubeeluck, and C.B. Moskowitz Huntington's disease. Part 3: family aspects of HD Br J Nurs 17 2008 328 331
3. G. Bates Huntingtin aggregation and toxicity in Huntington's disease Lancet 361 2003 1642 1644
4. E. Cattaneo, C. Zuccato, and M. Tartari Normal huntingtin function: an alternative approach to Huntington's disease Nat Rev Neurosci 6 2005 919 930
5. S.W. Davies, M. Turmaine, B.A. Cozens, M. DiFiglia, A.H. Sharp, and C.A. Ross Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation Cell 90 1997 537 548
6. M. Diaz-Hernandez, J. Torres-Peraza, A. Salvatori-Abarca, M.A. Moran, P. Gomez-Ramos, and J. Alberch Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease J Neurosci 25 2005 9773 9781
7. M. DiFiglia, E. Sapp, K. Chase, C. Schwarz, A. Meloni, and C. Young Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons Neuron 14 1995 1075 1081
8. M. DiFiglia, E. Sapp, K.O. Chase, S.W. Davies, G.P. Bates, and J.P. Vonsattel Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain Science 277 1997 1990 1993
9. R.J. Ferrante, N.W. Kowall, and E.P. Richardson Jr. Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry J Neurosci 11 1991 3877 3887
10. Y.P. Goldberg, B. Kremer, S.E. Andrew, J. Theilmann, R.K. Graham, and F. Squitieri Molecular analysis of new mutations for Huntington's disease: intermediate alleles and sex of origin effects Nat Genet 5 1993 174 179
11. S.M. Hersch, and H.D. Rosas Neuroprotective therapy for Huntington's disease: new prospects and challenges Expert Rev Neurother 1 2001 111 118
12. S.M. Hersch, and H.D. Rosas Neuroprotection for Huntington's disease: ready, set, slow Neurotherapeutics 5 2008 226 236
13. A. Hodges, A.D. Strand, A.K. Aragaki, A. Kuhn, T. Sengstag, and G. Hughes Regional and cellular gene expression changes in human Huntington's disease brain Hum Mol Genet 15 2006 965 977
14. L.S. Kaltenbach, E. Romero, R.R. Becklin, R. Chettier, R. Bell, and A. Phansalkar Huntingtin interacting proteins are genetic modifiers of neurodegeneration PLoS Genet 3 2007 e82
15. A.G. Kazantsev Cellular pathways leading to neuronal dysfunction and degeneration Drug News Perspect 20 2007 501 509
16. A.G. Kazantsev, and L.M. Thompson Therapeutic application of histone deacetylase inhibitors for central nervous system disorders Nat Rev Drug Discov 7 2008 854 868
17. B. Kremer, P. Goldberg, S.E. Andrew, J. Theilmann, H. Telenius, and J. Zeisler A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats N Engl J Med 330 1994 1401 1406
18. A.R. La Spada, H.L. Paulson, and K.H. Fischbeck Trinucleotide repeat expansion in neurological disease Ann Neurol 36 1994 814 822
19. W. Liu, L.A. Kennington, H.D. Rosas, S. Hersch, J.H. Cha, and P.D. Zamore Linking SNPs to CAG repeat length in Huntington's disease patients Nat Methods 5 2008 951 953
20. M.M. Maxwell RNAi applications in therapy development for neurodegenerative disease Curr Pharm Des 15 2009 3977 3991
21. P.J. Muchowski Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones? Neuron 35 2002 9 12
22. F.C. Nucifora Jr., M. Sasaki, M.F. Peters, H. Huang, J.K. Cooper, and M. Yamada Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity Science 291 2001 2423 2428
23. L.R. Pattison, M.R. Kotter, D. Fraga, and R.M. Bonelli Apoptotic cascades as possible targets for inhibiting cell death in Huntington's disease J Neurol 253 2006 1137 1142
24. L.H. Poon, G.A. Kang, and A.J. Lee Role of tetrabenazine for Huntington's disease-associated chorea Ann Pharmacother 44 2010 1080 1089
25. H.D. Rosas, D.H. Salat, S.Y. Lee, A.K. Zaleta, N. Hevelone, and S.M. Hersch Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease? Ann N Y Acad Sci 1147 2008 196 205
26. E. Scherzinger, R. Lurz, M. Turmaine, L. Mangiarini, B. Hollenbach, and R. Hasenbank Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo Cell 90 1997 549 558
27. J. Shao, and M.I. Diamond Polyglutamine diseases: emerging concepts in pathogenesis and therapy Hum Mol Genet 16 2007 R115 R123 (Spec. No. 2)
28. J.S. Steffan, A. Kazantsev, O. Spasic-Boskovic, M. Greenwald, Y.Z. Zhu, and H. Gohler The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription Proc Natl Acad Sci U S A 97 2000 6763 6768
29. R. Truant, R.S. Atwal, C. Desmond, L. Munsie, and T. Tran Huntington's disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases FEBS J 275 2008 4252 4262
30. A. Yamamoto, J.J. Lucas, and R. Hen Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease Cell 101 2000 57 66